Drug Profile


Alternative Names: SC 54684; SC 54684A; Xemlofiban

Latest Information Update: 09 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Searle.
  • Class Benzamidines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 09 Dec 2015 Xemilofiban is still available for out-licensing or co-development opportunities (http://www.virtualdrugdevelopment.com)
  • 01 Oct 2003 Xemilofiban is available for licensing (www.vddipharmaceuticals.com)
  • 12 Feb 2003 Clinical trials in Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top